{
    "X_si0": "Participants were eligible to continue with the 18-and 36-month follow-up if they had all of their doses of vaccine and a 7-month blood sample collected.  An external advisory panel and data and safety monitoring board were created by the Michael Smith Foundation for Health Research to oversee the study conduct and participant safety.  Women were not randomized and received the standard 0-, 2-, and 6-month vaccine schedule (FIGURE 1and FIGURE 2). ",
    "X_si1": "-s-Blinding of outcome assessment"
}
